OBJECTIVE: The aim was to investigate the impact of polycystic ovary syndrome (PCOS) on the regulation of lipolysis by catecholamine and for the first time atrial natriuretic peptide (ANP) before and after 16 wk of aerobic training. PATIENTS: Eight hyperandrogenic obese women with PCOS [age, 25 +/- 1 yr; body mass index (BMI), 32.0 +/- 1.6 kg/m(2)] and seven healthy BMI-matched controls participated. Studies were performed before and after a 16-wk exercise training program in women with PCOS and cross-sectionally in a group of BMI-matched controls. MAIN OUTCOME MEASURES: Lipolysis was measured in vitro in isolated adipocytes and in vivo by microdialysis of sc abdominal adipose tissue before and during a hyperinsulinemic euglycemic clamp. RESULTS: In vitro, baseline and maximal ANP- and isoproterenol-induced lipolysis was markedly reduced in PCOS women. Baseline (P < 0.001) and ANP-(P < 0.01) and isoproterenol-(P < 0.001) mediated lipolysis, however, was remarkably increased after training, independent of changes in body weight and sex hormones. These functional improvements were supported by an increased 1) lipolytic sensitivity for ANP (1.3-fold; P < 0.05); 2) lipolytic responsiveness for isoproterenol (1.7-fold; P < 0.01); and 3) postreceptor-acting agent dibutyryl-cAMP (activating cAMP-dependent protein kinase) (2.1-fold; P < 0.05). In vivo, the lipolytic responsiveness to isoproterenol was also reduced in PCOS and tended to increase after exercise training. The insulin suppression of lipolysis during the hyperinsulinemic euglycemic clamp was also reduced in PCOS. CONCLUSIONS: Together, these data show that the regulation of lipolysis by the main endocrine hormones is impaired in women with PCOS. These lipolytic defects can be partly reversed by aerobic exercise training independent of changes in body fat mass and sex hormones.
OBJECTIVE: The aim was to investigate the impact of polycystic ovary syndrome (PCOS) on the regulation of lipolysis by catecholamine and for the first time atrial natriuretic peptide (ANP) before and after 16 wk of aerobic training. PATIENTS: Eight hyperandrogenic obesewomen with PCOS [age, 25 +/- 1 yr; body mass index (BMI), 32.0 +/- 1.6 kg/m(2)] and seven healthy BMI-matched controls participated. Studies were performed before and after a 16-wk exercise training program in women with PCOS and cross-sectionally in a group of BMI-matched controls. MAIN OUTCOME MEASURES: Lipolysis was measured in vitro in isolated adipocytes and in vivo by microdialysis of sc abdominal adipose tissue before and during a hyperinsulinemic euglycemic clamp. RESULTS: In vitro, baseline and maximal ANP- and isoproterenol-induced lipolysis was markedly reduced in PCOSwomen. Baseline (P < 0.001) and ANP-(P < 0.01) and isoproterenol-(P < 0.001) mediated lipolysis, however, was remarkably increased after training, independent of changes in body weight and sex hormones. These functional improvements were supported by an increased 1) lipolytic sensitivity for ANP (1.3-fold; P < 0.05); 2) lipolytic responsiveness for isoproterenol (1.7-fold; P < 0.01); and 3) postreceptor-acting agent dibutyryl-cAMP (activating cAMP-dependent protein kinase) (2.1-fold; P < 0.05). In vivo, the lipolytic responsiveness to isoproterenol was also reduced in PCOS and tended to increase after exercise training. The insulin suppression of lipolysis during the hyperinsulinemic euglycemic clamp was also reduced in PCOS. CONCLUSIONS: Together, these data show that the regulation of lipolysis by the main endocrine hormones is impaired in women with PCOS. These lipolytic defects can be partly reversed by aerobic exercise training independent of changes in body fat mass and sex hormones.
Authors: J Polak; C Moro; E Klimcakova; J Hejnova; M Majercik; N Viguerie; D Langin; M Lafontan; V Stich; M Berlan Journal: Diabetologia Date: 2005-11-05 Impact factor: 10.122
Authors: Cédric Moro; Jan Polak; Blanka Richterova; Coralie Sengenès; Terezie Pelikanova; Jean Galitzky; Vladimir Stich; Max Lafontan; Michel Berlan Journal: Metabolism Date: 2005-01 Impact factor: 8.694
Authors: Mikael Rydén; Johan Jocken; Vanessa van Harmelen; Andrea Dicker; Johan Hoffstedt; Mikael Wirén; Lennart Blomqvist; Aline Mairal; Dominique Langin; Ellen Blaak; Peter Arner Journal: Am J Physiol Endocrinol Metab Date: 2007-02-27 Impact factor: 4.310
Authors: Coralie Sengenes; Anne Bouloumie; Hans Hauner; Michel Berlan; Rudi Busse; Max Lafontan; Jean Galitzky Journal: J Biol Chem Date: 2003-09-10 Impact factor: 5.157
Authors: Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: Jeffrey D Covington; Sudip Bajpeyi; Cedric Moro; Yourka D Tchoukalova; Philip J Ebenezer; David H Burk; Eric Ravussin; Leanne M Redman Journal: Eur J Endocrinol Date: 2014-10-23 Impact factor: 6.664
Authors: Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert Journal: Endocr Rev Date: 2012-07-24 Impact factor: 19.871
Authors: Oleg Varlamov; Michael P Chu; Whitney K McGee; Judy L Cameron; Robert W O'Rourke; Kevin A Meyer; Cecily V Bishop; Richard L Stouffer; Charles T Roberts Journal: Endocrinology Date: 2013-09-05 Impact factor: 4.736
Authors: Baogang J Xu; Wenwei Yan; Bojana Jovanovic; Aubie K Shaw; Qi A An; Jimmy Eng; Anna Chytil; Andrew J Link; Harold L Moses Journal: Cancer Microenviron Date: 2010-04-13
Authors: Júlio C de Almeida; Clodoaldo L Alves; Luiz Carlos de Abreu; Monica A Sato; Fernando L Fonseca; Carlos B de Mello Monteiro; Luiz Carlos M Vanderlei; Hugo Macedo; Carlos M Tavares; Dafne Herrero; Luciano Mr Rodrigues; Vitor E Valenti Journal: Int Arch Med Date: 2012-02-07